 Ravi Bellamkonda, PhD
GCC Distinguished Cancer Scholar
Professor of Biomedical Engineering
Georgia Institute of Technology / Emory University
Dr. Bellamkonda is a Professor of Biomedical Engineering in the Joint Coulter Department of Biomedical Engineering at Georgia Tech/Emory. He earned his PhD at Brown University, Providence, Rhode Island, and completed his post-doctoral training at M.I.T in Cambridge, Massachusetts. Prior to moving to Georgia Tech in 2003, he was a tenured Associate Professor at Case Western Reserve University in Cleveland, Ohio. Dr. Bellamkonda's research interests include applying nanotechnology and biomaterials for personalizing therapy for cancer patients through the use of novel contrast agent and drug delivery systems. His research also focuses on applying biomaterials based technologies for the repair and regeneration of the nervous system, including bridging long peripheral nerve gaps, overcoming regenerative failure in the central nervous system, and interfacing electrodes with the brain.
Professor Bellamkonda leads the Neural Tissue Engineering programmatic thrust at GTEC, a National Science Foundation funded Engineering Research Center based at Georgia Tech/Emory. He is an active member of the Brain Tumor Program at the Winship Cancer Center at Emory. Prof. Bellamkonda has been appointed Georgia Cancer Coalition Distinguished Scholar in recognition of his work in personalized cancer diagnosis and therapy. He has received numerous awards including a CAREER award and Globus Indus Technovator award. Dr. Bellamkonda is a Fellow of American Institute of Medical and Biological Engineering and the Institute of Physics. He serves on the editorial board of Journal of Neuroengineering, IEEE Transactions on Neural Systems, and Rehabilitation and Experimental Biology and Medicine and is the Founding Scientist of both Marval Therapeutics, Inc. and Regeneration Matrix, Inc. His research is funded by grants from the National Institutes of Health, National Science Foundation, Georgia Cancer Coalition, Ian's Friends Foundation, Coulter Foundation, and Whitaker Foundation.
 Kapil Bhalla, MD
Director, Cancer Center and
Vice-Dean for Cancer Research and Services,
Medical College of Georgia, Augusta
GCC Distinguished Cancer Scholar
Georgia Research Alliance Eminent Scholar
Cecil F. Whitaker Chair in Cancer
Chief, Clinical Cancer Services, Medical College of Georgia Health, Inc.
Dr. Kapil Bhalla is Director of the Cancer Center and Vice-Dean for Cancer Research and Services at the Medical College of Georgia in Augusta and Chief of Clinical Cancer Services at Medical College of Georgia Health. He is a Georgia Cancer Coalition Distinguished Cancer Scholar, a Georgia Research Alliance Eminent Scholar and holds the Cecil F. Whitaker Chair in Cancer.
A 1976 graduate of the University of Delhi’s Maulana Azad Medical College in India, Dr. Bhalla completed internships in pathology and internal medicine and a residency in internal medicine at St. Michael’s Medical Center in N.J. He did a post-doctoral fellowship in hematology and oncology at Columbia University College of Physicians and Surgeons in New York and subsequently served on the faculties of Columbia University, Medical University of South Carolina, Emory University, University of Miami and University of South Florida and Moffitt Cancer Center. Board-certified in Internal Medicine, Hematology and Medical Oncology, Dr. Bhalla is a member of ASCO, the American Society of Hematology (ASH) and AACR. He is a past recipient of the ACS’s Career Development Award and the Leukemia Society of America’s Fellow and Scholar Awards. Dr. Bhalla is a former member of the NIH’s Experimental Therapeutics Study Section and a former Chair of the Developmental Therapeutics Study Section. He serves as the associate editor of Cancer Research and is a member of the editorial boards Blood, Clinical Cancer Research, Molecular Cancer Therapeutics, Cell Cycle and Cancer Biology and Therapy. Dr. Bhalla’s research focus is cancer epigenetics and chaperone biology as well as novel targeted therapeutics against signaling proteins in leukemia and breast cancer.
 Steven T. Brower, MD, FACS
Director, Curtis & Elizabeth Anderson Cancer Institute
Senior Vice President, Oncology & Research
Memorial University Medical Center, Savannah
Professor & Chairman, Department of Surgery,
Mercer University School of Medicine—Savannah Campus
Georgia Cancer Coalition Distinguished Cancer Scholar
Dr. Steven Brower is Director of the Curtis and Elizabeth Anderson Cancer Institute and Senior Vice President of Oncology and Research at Memorial University Medical Center in Savannah. He is also Professor and Chairman of the Department of Surgery at Mercer University’s School Of Medicine, Savannah campus. Dr. Brower is a Georgia Cancer Coalition Distinguished Cancer Scholar.
Dr. Brower graduated from medical school at the State University of New York at Buffalo and completed his general surgery residency at the Lahey Clinic, Boston University Medical Center. He also completed a fellowship in Surgical Oncology at the National Cancer Institute, National Institutes of Health, American Cancer Society, Boston University Medical Center. Before joining Memorial University Medical Center, he served as the Chief of the Division of Surgical Oncology at Mount Sinai Medical Center, New York. Dr. Brower’s clinical expertise includes complex cancers of the esophagus, liver, pancreas and gastrointestinal tract; and laparoscopic approaches to benign and malignant diseases. He was identified in Best Doctors in America and in the Nation and received the ACS Clinical Oncology Career Development Award, among numerous other accolades. His research interests include identifying serum protein and gene expression profiles for GI cancers; biomarker discovery for diagnosis/early detection, prognosis, and monitoring GI cancers; comparison of protein and gene expression profiles to specific tumor type and correlating to tumor differentiation and clinical outcome; minimally invasive approaches to liver cancer; identifying novel proteins involved in PANIN transformation of the pancreas; and new approaches to treating patients at high risk for esophageal cancer.
 Walter J. Curran, MD
Executive Director, Emory Winship Cancer Institute
Georgia Cancer Coalition (GCC) Distinguished Cancer Scholar
Dr. Walter Curran is Executive Director of Emory WCI and a GCC Distinguished Cancer Scholar. He has served as the Lawrence W. Davis Professor and Chairman of Emory’s Department of Radiation Oncology and as chief medical officer of Emory Winship. He joined Emory in 2008, from Jefferson Medical College in Philadelphia, where he was professor and chair of Radiation Oncology and clinical director for Jefferson’s Kimmel Cancer Center. He currently serves as Group Chairman and Principal Investigator of the Radiation Therapy Oncology Group (RTOG), an NCI-funded cooperative group.
An international expert in the management of patients with locally advanced lung cancer and malignant brain tumors, Dr. Curran has led several landmark clinical and translational trials in both areas. He is responsible for defining a universally adopted staging system for patients with malignant glioma. He has authored or co-authored more than four hundred abstracts and scholarly papers and numerous presentations, reviews and book chapters. He has been chairman or co-chairman of more than 40 clinical trials and a reviewer for twelve national/international journals. He is Founding Secretary/Treasurer of the Coalition of Cancer Cooperative Groups and a Board Member of the Georgia Center for Oncology Research and Education (Georgia CORE).
A Fellow in the American College of Radiology, Dr. Curran has been awarded honorary memberships in the European Society of Therapeutic Radiology and Oncology and the Canadian Association of Radiation Oncology. In 2006, he was named the leading radiation oncologist/cancer researcher in a peer survey by the journal Medical Imaging. Under his leadership, Emory’s Radiation Oncology Department was selected a “Top Five Radiation Therapy Centers to Watch in 2009” by Imaging Technology News.
Dr. Curran graduated cum laude from Dartmouth College, received his MD degree from the Medical College of Georgia and is a Board Certified Radiation Oncologist. He completed his residency in the Department of Radiation Therapy at the University of Pennsylvania Medical Center and his internship in internal medicine at Presbyterian University of Pennsylvania Medical Center in Philadelphia.
 Judith Giri, PhD
Associate Professor, Pathology
Medical College of Georgia, Augusta
Director, MCG Tumor, Tissue and Serum Biorepository
Director, Biorepository Alliance of Georgia for Oncology (BRAG-Onc)
GCC Distinguished Cancer Scholar
Dr. Giri is an Associate Professor in the Department of Pathology at the Medical College of Georgia in Augusta and member of the MCG Cancer Center. She also serves as the Director for both the MCG Tumor Tissue and Serum Biorepository and the Biorepository Alliance of Georgia for Oncology. She is a Georgia Cancer Coalition Distinguished Cancer Scholar.
Dr. Giri obtained her PhD in Microbiology from Rutgers University, New Brunswick, New Jersey, and completed post-doctoral training and fellowships at the Roche Institute of Molecular Biology, Columbia University, and Pennsylvania State University. Dr. Giri’s current interest is in biobanking, establishing a biorepository in GA with high quality specimens and informatics, to support basic and translational cancer research. Her research interests have focused on cytokines and growth factors and the identification of novel therapeutic targets and biomarkers for cancer. Prior to joining MCG she lead discovery research in biotechnology in Oncology and Autoimmune Diseases
 Susan Irby
Client Services Manager,
Maestro Strategies LLC, Atlanta
Susan Irby has twenty four years experience in the healthcare industry in both the provider and consulting arenas. As the Decision Support Practice Leader for Maestro Strategies, LLC, in Atlanta, she provides clients with expertise in strategic financial planning, cost accounting, information technology and value improvement processes. She has served the Georgia Cancer Coalition as Project Manager for its Georgia Cancer Quality Information Exchange demonstration and technology proof of concept project. Ms. Irby is co-author of Beyond Return on Investment: Expanding the Value of Healthcare Information Technology which defines measurement tools and techniques to assist organizations in their transformational efforts. She earned a BIE and MSHS from Georgia Institute of Technology.
 Shafiq Khan, PhD
Professor and Georgia Research Alliance Eminent Scholar
Director, Center for Cancer Research and Therapeutic Development
Director, NIH/NCMHD Center of Excellence in Prostate Cancer Research, Education and Community Services
Clark Atlanta University, Atlanta
Dr. Khan is Director of the Center for Cancer Research and Therapeutic Development and Professor at Clark Atlanta University, as well as the Director of its NIH-designated National Center on Minority Health and Health Disparities Center of Excellence in Prostate Cancer Research, Education and Community Services. He is a Georgia Research Alliance Eminent Scholar.
Dr. Khan earned his MSc in Biological Sciences and MPhil in Reproductive Physiology at QA University in Pakistan. He received his PhD and did postdoctoral training in Reproductive Endocrinology at Sweden’s Karolinska Institute. Before being recruited to Georgia in 2004, Dr. Khan did research at the Max Planck Clinical Research Unit, University of Muenster, Germany; the University of Toronto; The Women's Research Institute at the University of Kansas School of Medicine; and at the Department of Cell Biology and Biochemistry, the Southwest Cancer Center and the Center for Biotechnology and Genomics at Texas Tech University Health Sciences Center. His research interests include the role of growth factors and cytokines in the regulation of gonadal cell proliferation, differentiation and function and in development of ovarian and prostate cancers; signal transduction mechanisms involved in the regulation of cell-cycle and differentiated function of normal and transformed cells; identification, isolation, mechanism of action and physiological significance of bioactive proteins and peptides in male and female gonads; and molecular and cellular endocrinology of gonadal function and development.
 Amy Moore, Ph.D.
Manager, Research Programs
Georgia Cancer Coalition
Dr. Moore is Manager of Research Programs at the Georgia Cancer Coalition, responsible for overseeing the operation and evaluation of the Distinguished Cancer Clinicians and Scientists program; Cancer Research Awards; and the BioRepository Alliance of Georgia for Oncology. She earned her Bachelor of Science degree in Biology from Furman University in Greenville, South Carolina, and her Ph.D. in Microbiology and Immunology from Wake Forest University School of Medicine in North Carolina. She was an NIH Training Grant Postdoctoral Fellow at the University of Michigan Medical School and at Vanderbilt University Medical Center she worked on an NIH Training Grant and an ACS Postdoctoral Fellowship in cancer research. At Furman, Wake Forest and Vanderbilt Universities she also served as a teaching assistant, lecturer, course director and mentor to graduate and undergraduate students. She is a Fellow in Training of the American Society of Hematology, an Associate Member of AACR, and a Member of AACR-Women in Cancer Research, the National Postdoctoral Association, and the American Association for the Advancement of Science. In 2007, she was honored with the AACR-Aflac, Incorporated Scholar-In-Training Award.
 Nancy Paris
President and CEO
Georgia Center for Oncology Research and Education
Nancy Paris is President and Chief Executive Officer of the Georgia Center for Oncology Research and Education. She has extensive experience creating, directing and raising funds to support community-based health programs. Prior to initiating Georgia CORE in 2005, she served as vice-president and interim president of the Georgia Cancer Coalition; president of Saint Joseph’s Mercy Care Services; and vice-president of the Georgia Baptist Health Care System. She also served as director of Hospice Atlanta, vice-president of the Visiting Nurse Foundation and president of AID Atlanta. She currently chairs the Georgia Health Foundation. Ms. Paris is a Fellow of the American College of Healthcare Executives and the Health Forum. She earned a bachelor’s degree in Sociology from the University of Georgia, a certificate in gerontology from Georgia State University and a master’s degree in Health Policy and Administration from Mercer University in Macon, Georgia. In 2002, she was named Woman of the Year in Healthcare by Women Healthcare Executives of Atlanta.
 Michael Pierce, PhD
Director, Cancer Center
University of Georgia, Athens
Dr. Michael Pierce is the Director of the Cancer Center at the University of Georgia in Athens. He serves as the George E. and Sarah F. Peters Mudter Professor in Cancer Research and Distinguished Research Professor of Biochemistry and Molecular Biology and a member of the Complex Carbohydrate Research Center. He joined UGA in 1991 as an Associate Professor.
During his tenure at UGA, he has received more than $23 million in grants from NCI and NIH and was honored with the prestigious 5-year Faculty Research Award from the American Cancer Society. Dr. Pierce is the Principal Investigator of the National Center for Research Resources Integrated Resource for Biomedical Glycomics and the NCI Tumor Glycomics Laboratory for Pancreatic Cancer Marker Discovery. He serves as a reviewer for various organizations including NCI, ACS, and NCRR. He is an inventor on fourteen US Patents. Dr. Pierce received his BS in Chemistry/Biology from Oklahoma Baptist University in 1973, and his PhD in Biology from the Johns Hopkins University in 1980. From 1979-1982, he was an NIH Postdoctoral Fellow in Biochemistry at the University of California, Berkeley. He was a Staff Investigator and Associate Professor in the Papanicolau Comprehensive Cancer Center at the University of Miami Medical School from 1982-1991.
 Kimberly C. Redding, MD, MPH
Director, Health Promotion and Disease Prevention Programs
Division of Public Health, Georgia Department of Community Health
Dr. Kimberly Redding is Director of Health Promotion and Disease Prevention programs in the Division of Public Health of the Georgia Department of Community Health.
She earned a BS in Zoology at Howard University in Washington, DC and her Medical Degree at the Morehouse School of Medicine. She completed residency training in Anatomic and Clinical Pathology, and a fellowship in gynecological pathology at the Emory University School of Medicine. She studied for her MPH in Health Policy at Emory’s Rollins School of Public Health and did a second residency in Public Health and Preventive Medicine at Morehouse. Dr. Redding is board certified in Anatomic and Clinical Pathology and board eligible in Preventive Medicine. She has provided leadership in Cancer Control through Georgia’s Division of Public Health and the Department of Human Resources since 2001.
 E. Shyam P Reddy, PhD
Georgia Cancer Coalition Distinguished Cancer Scholar,
Professor and Co-Director, Cancer Biology Program,
Department of OB/GYN, Georgia Cancer Center for Excellence,
Grady Health System, Atlanta, GA
Dr Shyam Reddy is Professor and Co-Director of the Cancer Biology Program at Morehouse School of Medicine in Atlanta and the Georgia Cancer Center for Excellence at Grady Memorial Hospital.
He discovered and cloned several oncogenes and studied their functions, in collaboration with Dr Veena Rao. The most notable genes discovered include ERG-1 and ERG-2 genes (ETS Related Gene) involved in 40-80% of prostate cancers, Ewing sarcoma and also leukemias (AML). Other notable genes discovered and studied by Dr Reddy include human Fli-1 (involved in Leukemias), EWS-Fli-1 (involved in Ewing Sarcoma, Pediatric cancer) , EWS-erg (involved in Ewing Sarcoma), TLS-erg (involved in Acute Myeloid Leukemia), EWS (involved in multiple cancers), TLS/FUS (involved in multiple cancers), ELK-1 (ETS Like Gene), BRCA2a (involved in breast, ovarian and prostate cancers) and EWS-ATF-1 (involved in malignant Melanoma of Soft Parts). Drs Reddy, Rao, Matthews and Yao are collaborating in identifying the function of oncogenes and targeting the oncoproteins or their functions to develop novel targeted therapeutic agents. Using this function-based therapeutic strategy (functionotherapeutics), they have developed several novel drugs (patent submitted) that target prostate, Ewing sarcoma, triple negative breast cancers, pancreatic cancer, ovarian cancers etc. Dr Reddy and his group has recently discovered novel post-translational mechanism that will have global effects on the gene expression, differentiation, protein turnover, cell death, cancer and other human diseases. He predicts that this CBP/p300-mediated post-translational modification may be a signal for degradation/turnover of CBP interacting proteins.
 Lisa Richardson, MD
Medical Officer, Team Lead , Scientific Support and Clinical Translation Team
Comprehensive Cancer Control Branch,
Center for Disease Control and Prevention, Atlanta
Dr. Lisa Richardson is medical officer and Team Lead of the Scientific Support and Clinical Translation Team in the Comprehensive Cancer Control Branch of the Centers for Disease Control and Prevention in Atlanta. She is board certified in Hematology and Medical Oncology. Dr. Richardson graduated from the University of North Carolina in 1989, and completed internship, residency and fellowship training at the University of Florida. In addition, she received her master’s degree in Epidemiology from the University of Michigan in 1997. Her research focuses on access to cancer care, systems of care, health-related quality of life during treatment, and patterns of treatment of breast cancer.
 William J. Todd
President and Chief Executive Officer,
Georgia Cancer Coalition
Bill Todd has served as president of the Georgia Cancer Coalition since 2003. Immediately prior to joining the Coalition, he served as Executive Director of the Commission for a New Georgia.
Mr. Todd was the founder of Encina Technology Ventures, an early-stage technology venture capital fund in partnership with Atlanta developer Tom Cousins. He was the founding president of the Georgia Research Alliance, a strategic partnership of the six research universities in Georgia, joined by the business community and state government, whose purpose is to grow and leverage the State’s research capabilities into economic development results. In the first half of his professional career, he held various administrative positions in the Emory University System of Health Care, at hospitals, clinics, and the school of medicine, including Assistant Vice President for Medical Administration at the Robert W. Woodruff Health Sciences Center. Mr.Todd is a graduate of Georgia Institute of Technology. He is President of Georgia Tech’s Foundation Board and serves as a member on numerous other civic and corporate boards.
 Binghe Wang, PhD
Professor, Department of Chemistry
Georgia State University, Atlanta
GCC Distinguished Cancer Scholar
Georgia Research Alliance Eminent Scholar in Drug Discovery
Dr. Binghe Wang is a medicinal chemistry professor at Georgia State University. He is also a Georgia Research Alliance Eminent Scholar in Drug Discovery and a Georgia Cancer Coalition Distinguished Cancer Scholar. He serves as Editor-in-Chief of Medicinal Research Reviews and is the founding editor of a book series entitled “Wiley Series in Drug Discovery and Development.” Professor Wang’s research interests include drug design and synthesis, molecular recognition, and new diagnostics. His lab is currently working on the design and synthesis of phosphodiesterase inhibitors, in collaboration with Professor Roberto Docampo of UGA; bacterial SecA inhibitors, in collaboration with Professor P.C. Tai of Georgia State University; HIF-1 inhibitors, in collaboration with Professor Erwin Van Meir of Emory; and bacterial quorum sensing inhibitors, in collaboration with Professor Chung-dar Lu of Georgia State University. His lab is also studying new MRI contrast agents for cancer detection in collaboration with Professors Weili Lin and Kim Rathmell of University of North Caroline and aptamers for glycoproteins aimed at detecting cancer biomarkers with the ability to differentiate glycosylation patterns, in collaboration with Professor Zhen Huang of Georgia State University.
 Howard Zaren, MD
Principal Investigator, NCCCP project at SJ/CH pilot site
Medical Director, Cancer Program,
Lewis Cancer Research Program
St. Joseph’s/Candler Hospital, Saint Joseph’s Candler Health System, Savannah
GCC Distinguished Cancer Scholar
Dr. Howard Zaren is Medical Director of the Cancer Program at the Lewis Cancer Research Pavilion at St. Joseph’s/Candler Hospital in Savannah and Principal Investigator with the NIH Community Clinical Care Program at the St. Joseph’s/Candler pilot site. He is a Georgia Cancer Coalition Distinguished Cancer Scholar.
In 2008, Dr. Zaren was recruited to Georgia from Chicago, Illinois, where he chaired the Department of Surgery at John H. Stronger, Jr. Hospital of Cook County; served as Principal Investigator for the Minority Based Community Clinical Oncology Program; and was a tenured professor of Oncology at the University of Illinois. He is fellowship trained in surgical oncology and gastrointestinal endoscopy from MD Anderson Hospital and Tumor Institute at the University of Texas Cancer Center. He graduated with his doctorate of medicine from the University of Manitoba Medical School in Manitoba, Canada and performed his internship and residency at Pennsylvania Hospital. He is a fellow of the American College of Surgeons. Dr. Zaren’s research interests include breast cancer, sarcoma, melanoma, minority-underserved clinical oncology, clinical trial protocols for treatment of cancers, and tumor tissue procurement for cancer genomics.
Friday, November 6
Survivor Panel
 Courtney Bugler
Executive Director
Young Survival Coalition/Atlanta affiliate
Courtney Bugler is a breast cancer survivor, diagnosed at age 29. She is a trained hotline counselor for Breast Cancer Network of Strength; a member of the Cancer Survivor Leadership Council of Georgia; the Southeastern Regional Chair of "I’m too Young for This!", an advocacy group for adolescent and young adult cancer survivors; and is the youngest member of the "Shades of Pink Breast Cancer Survivor gospel choir." After volunteering as chair of The Young Survival Coalition’s Atlanta affiliate, Courtney gave up her career as a television scriptwriter to devote herself to helping young women affected by this disease. She’s now Executive Director of the Atlanta office, responsible for affiliate operations. She is a graduate of National Breast Cancer Coalition’s Quality Care project LEAD, the Project LEAD Institute, the Harold Freeman Patient Navigation Institute, the Alamo Breast Cancer Leaders project and is a trained member of Susan G. Komen's Advocates in Science. As Atlanta media spokesperson for the Breast Cancer 3-day and cancer community activist, Courtney has been interviewed by local and national media, including Lifetime Television’s 2008 “Living Proof” PSA and viewing guide; this winter, her young survivor advocacy article will be featured in Reader's Digest. Courtney has lobbied both nationally for breast cancer and locally for fertility preservation rights of cancer survivors; she recently had her first baby.
John Davis, EdD, Retired Educator
John Davis worked in the field of education for 26 years before he was forced to retire with a disability at age 47 due to residual affects of surgery, chemotherapy and radiation to treat a non-Hodgkin’s lymphoma spinal tumor. He earned his Bachelors Degree at Livingstone College in North Carolina; a Master of Arts from Atlanta University, now known as Clark Atlanta; and the EdD at University of Georgia. After a year of teaching junior high school reading in Charlotte, North Carolina, he relocated to Athens, Georgia, and continued his teaching career as a high school English teacher.
Following several years of school, John continued in his profession as assistant and associate principal in a middle school and a high school respectively. When he retired, he was an elementary school principal. Since his retirement, Dr. Davis has done extensive volunteering, both with his church, Greater Bethel AME, and in the field of mental health. He was board chairman of the Northeast Georgia Community Services Board, which serves a 10-county area around Athens. More recently, he presided over the Georgia Association of Community Services Boards, which represents 26 boards throughout the state. His wife, Dr. Katheryn Davis, is a professor emeritus with UGA’s School of Social Work.
 Markus W. Germann, Ph.D
Professor, Associate Graduate Director
Biophysical Chemistry
Georgia State University, Atlanta
GCC Distinguished Cancer Scholar
Dr. Markus Germann is Professor of Biophysical Chemistry and Associate Graduate Director at Georgia State University in Atlanta. He is a Georgia Cancer Coalition Distinguished Cancer Scholar.
Dr. Germann has worked for years on exploring how the body fixes damaged DNA; damage he has experienced personally. A former smoker, he was diagnosed with oral cancer in 2007 and underwent surgery, radiation and chemotherapy; he is now in remission. Dr. Germann earned his MS at Technikum Winterthur in Switzerland and did his PhD studies and postdoctoral work at the University of Calgary in Alberta, Canada. Prior to joining Georgia State University, he was Associate Professor at Thomas Jefferson University, Kimmel Cancer Institute, Departments of Microbiology and Immunobiology in Pennsylvania. His research interests are in structural and functional studies of nucleic acids and proteins and DNA mutations and genetic errors that can ultimately cause cancer.
Friday Oral Presentation Speaker Biographies |
